CA3149175A1 - Nitenin analogue compounds and their use in the treatment of chronic and acute pain - Google Patents
Nitenin analogue compounds and their use in the treatment of chronic and acute pain Download PDFInfo
- Publication number
- CA3149175A1 CA3149175A1 CA3149175A CA3149175A CA3149175A1 CA 3149175 A1 CA3149175 A1 CA 3149175A1 CA 3149175 A CA3149175 A CA 3149175A CA 3149175 A CA3149175 A CA 3149175A CA 3149175 A1 CA3149175 A1 CA 3149175A1
- Authority
- CA
- Canada
- Prior art keywords
- pain
- compound
- alkyl
- formula
- nitenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/36—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT11568519 | 2019-07-31 | ||
| PT115685 | 2019-07-31 | ||
| PCT/IB2020/056915 WO2021019373A1 (en) | 2019-07-31 | 2020-07-22 | Nitenin analogue compounds and their use in the treatment of chronic and acute pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3149175A1 true CA3149175A1 (en) | 2021-02-04 |
Family
ID=72240450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3149175A Pending CA3149175A1 (en) | 2019-07-31 | 2020-07-22 | Nitenin analogue compounds and their use in the treatment of chronic and acute pain |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12336977B2 (https=) |
| EP (1) | EP4003984A1 (https=) |
| JP (1) | JP2022544057A (https=) |
| CN (1) | CN114616230A (https=) |
| AU (1) | AU2020320115A1 (https=) |
| CA (1) | CA3149175A1 (https=) |
| IL (1) | IL290192A (https=) |
| MX (1) | MX2022001186A (https=) |
| WO (1) | WO2021019373A1 (https=) |
| ZA (1) | ZA202201154B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116115739A (zh) * | 2022-12-29 | 2023-05-16 | 张瑜 | 胃动素及其受体激动剂的应用 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4003984A1 (en) | 2019-07-31 | 2022-06-01 | Sea4Us - Biotecnologia e Recursos Marinhos, Lda. | Nitenin analogue compounds and their use in the treatment of chronic and acute pain |
| WO2026013449A2 (en) * | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7375136B2 (en) | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
| GB0305149D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
| WO2007009462A2 (en) | 2005-07-15 | 2007-01-25 | Region Hovedstaden V/Glostrup Hospital | Treatment of migraine and headaches |
| ES2345527B1 (es) | 2008-10-08 | 2011-09-08 | Hospital Clinic I Provincial De Barcelona | Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima. |
| KR101939401B1 (ko) | 2011-11-10 | 2019-01-16 | 가천대학교 산학협력단 | 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물 |
| CN106537149A (zh) * | 2014-04-01 | 2017-03-22 | 宝洁公司 | 用于筛选色氨酸通道的方法 |
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| CN106146530A (zh) * | 2015-04-14 | 2016-11-23 | 中国科学院生态环境研究中心 | 一种合成cephalosporolides E,F,H,I的新方法 |
| EP4003984A1 (en) | 2019-07-31 | 2022-06-01 | Sea4Us - Biotecnologia e Recursos Marinhos, Lda. | Nitenin analogue compounds and their use in the treatment of chronic and acute pain |
-
2020
- 2020-07-22 EP EP20761628.5A patent/EP4003984A1/en active Pending
- 2020-07-22 CN CN202080057704.6A patent/CN114616230A/zh active Pending
- 2020-07-22 JP JP2022506029A patent/JP2022544057A/ja active Pending
- 2020-07-22 CA CA3149175A patent/CA3149175A1/en active Pending
- 2020-07-22 AU AU2020320115A patent/AU2020320115A1/en active Pending
- 2020-07-22 MX MX2022001186A patent/MX2022001186A/es unknown
- 2020-07-22 WO PCT/IB2020/056915 patent/WO2021019373A1/en not_active Ceased
- 2020-07-22 US US17/631,135 patent/US12336977B2/en active Active
-
2022
- 2022-01-25 ZA ZA2022/01154A patent/ZA202201154B/en unknown
- 2022-01-27 IL IL290192A patent/IL290192A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116115739A (zh) * | 2022-12-29 | 2023-05-16 | 张瑜 | 胃动素及其受体激动剂的应用 |
| CN116115739B (zh) * | 2022-12-29 | 2024-01-09 | 天津市肿瘤医院（天津医科大学肿瘤医院） | 胃动素及其受体激动剂的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202201154B (en) | 2024-02-28 |
| IL290192A (en) | 2022-03-01 |
| CN114616230A (zh) | 2022-06-10 |
| AU2020320115A1 (en) | 2022-02-24 |
| WO2021019373A4 (en) | 2021-03-25 |
| US12336977B2 (en) | 2025-06-24 |
| MX2022001186A (es) | 2022-05-11 |
| JP2022544057A (ja) | 2022-10-17 |
| WO2021019373A1 (en) | 2021-02-04 |
| EP4003984A1 (en) | 2022-06-01 |
| US20220288017A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4154237B2 (ja) | 異痛症および他の種々のタイプの慢性疼痛または幻肢痛を治療するための化合物のペプチドクラスの新規使用 | |
| Berman et al. | Neurobehavioral protection by the neuronal calcium channel blocker ziconotide in a model of traumatic diffuse brain injury in rats | |
| US12336977B2 (en) | Nitenin analogue compounds and their use in the treatment of chronic and acute pain | |
| BRPI0613697A2 (pt) | tratamento de distúrbios de sono-vigìlia | |
| JP2025163030A (ja) | 慢性および急性疼痛の治療における使用のためのｋｖ１．３アンタゴニスト | |
| Adam et al. | Treatment of dystonia | |
| ES2348314T3 (es) | Derivados de mononitrato de isosorbida para el tratamiento de la hipertensión ocular. | |
| Marganella et al. | Comparative effects of levobupivacaine and racemic bupivacaine on excitotoxic neuronal death in culture and N-methyl-D-aspartate-induced seizures in mice | |
| ES2388876T3 (es) | Uso de [2-(2-metilimidazol-1-il)metil]piridina para tratamiento de trastornos del sueño | |
| AU2020322218B2 (en) | Kv1.3 antagonists for use in the treatment of chronic and acute pain | |
| HK40076622A (en) | Nitenin analogue compounds and their use in the treatment of chronic and acute pain | |
| Doyle et al. | Investigation of the actions and antagonist activity of some polyamine analogues in vivo | |
| EP1817029B1 (en) | Isoxazolic derivative to relieve neuropathic pain | |
| Saini et al. | Evaluation of intrathecal neostigmine for postoperative analgesia | |
| MXPA02006374A (es) | Combinacion de trimebutina con un opioide analgesico. | |
| CN105934245A (zh) | 多发性硬化症的治疗剂或预防剂 | |
| Ondo | Overview of the Medical Treatments of Hyperkinetic Disorders | |
| Tyrer et al. | Central Pain States: Etiology and Management in Rehabilitation | |
| HK1230501A1 (en) | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior | |
| HK1230501A (en) | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior | |
| GARCIA et al. | Animal models of REM dysfunctions: what they tell us about the cause of narcolepsy and RBD? | |
| Carinci et al. | MECHANISMS OF SPINAL ANALGESIA | |
| HK1143544A (en) | The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases | |
| HK1117402B (en) | Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders | |
| KR20030006576A (ko) | 라이소포스파티딘산을 포함하는 뇌졸중 예방 및 치료용조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240710 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240710 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241121 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250102 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250102 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250411 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250507 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250709 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250709 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250722 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251124 |